[ad_1]
Chengdu, China, January 5, 2022 (Global News Agency) – Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197)A global clinical stage biotechnology company that develops new vaccines and biotherapeutic drug candidates announced today that it has begun building a new R&D center in the Zhangjiang Biomedical Industry Base, called “Zhangjiang Medicine Valley”, located in the Zhangjiang High-Tech Park. Pudong, Shanghai. Zhangjiang Pharmaceutical Valley is one of China’s top biotechnology centers, with more than 1,000 innovative biotechnology and biopharmaceutical companies.
Clover owns more than 25,000 square meters of real estate for the construction of state-of-the-art facilities, which are expected to include new pre-clinical research laboratory facilities, manufacturing process development laboratories, and GMP pilot manufacturing plants. The construction of R&D facilities is expected to be completed in the second quarter of 2022, and the entire R&D center is scheduled to be completed in the second half of 2022. Clover plans to recruit hundreds of new employees from the region’s deep talent pool to supplement Clover’s existing R&D capabilities and accelerate the development of multiple new product candidates.
Joshua Liang, CEO of Clover Biopharmaceuticals Said, “Establish a new R&D center in Shanghai…
The full story can be found on Benzinga.com
[ad_2]
Source link
